{'fraction_non_alphanumeric': 0.047232472324723246, 'fraction_numerical': 0.04870848708487085, 'mean_word_length': 4.195402298850575, 'pattern_counts': {'":': 0, '<': 1, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Influence of trimetazidine on echocardiography parameters and free radical stress index in coronary artery disease and end-stage renal failure patients treated by hemodialysis: preliminary communication].

The aim of the study was the assessment of the influence of trimetazidine (TMZ) on echocardiography parameters and oxidative stress markers in hemodialyzed patients with coronary artery disease. The studies were carried out in 9 patients group before and after 3 months of TMZ treatment in doses 3 x 20 mg. Additionally we measured MDA concentration in the blood, as a oxidative stress marker, before and after 2 and 3 months of TMZ treatment. At the start of the study impairment of relaxation as a sign of diastolic dysfunction was detected. This abnormality persisted up to the end of the study. After 3 months of TMZ treatment we observed elevation of ejection fraction from 59.17 +/- 5.99 to 65.33 +/- 8.7% (p = 0.05). Also occurred statistically significant decrease in MDA level after 2 (0.674 +/- 0.029 vs 0.627 +/- 0.034; p < 0.001) and 3 (0.674 +/- 0.029 vs 0.567 +/- 0.063 mumol/L; p = 0.001) months of TMZ treatment. Significant improvement of the left ventricular function and decrease of MDA levels in the blood might be due to intracellular mechanisms of TMZ activity. There were no side effects of the drug in hemodialyzed patients.